uniQure (NASDAQ:QURE) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

uniQure (NASDAQ:QURE) had its price objective increased by The Goldman Sachs Group from $9.00 to $20.00 in a research note published on Thursday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biotechnology company’s stock.

QURE has been the subject of a number of other reports. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.14.

uniQure Stock Up 2.3 %

Shares of NASDAQ:QURE opened at $15.40 on Thursday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $17.39. The firm’s 50 day moving average price is $7.04 and its 200 day moving average price is $6.36. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $750.60 million, a price-to-earnings ratio of -3.10 and a beta of 0.89.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities research analysts predict that uniQure will post -3.81 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of uniQure during the 2nd quarter worth approximately $79,000. Assenagon Asset Management S.A. purchased a new stake in uniQure in the 2nd quarter valued at approximately $815,000. Privium Fund Management B.V. grew its holdings in uniQure by 10.6% during the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after buying an additional 61,501 shares during the last quarter. Finally, Doheny Asset Management CA acquired a new stake in uniQure during the 2nd quarter valued at $1,220,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.